期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

奈西立肽在治疗急性失代偿心力衰竭患者中的地位

Role of Nesiritide in Therapy of Patients with Acute Decompensated Heart Failure
下载PDF
导出
摘要 柰西立肽为一用重组DNA技术由大肠杆菌制成,具有如心室肌内源性产生的脑利钠肽相同的化学结构和生物学作用。2001年由美国FDA批准的强效扩血管药,最近已用于急性失代偿性心力衰竭患者治疗最新选择。国外文献报道它能短期内改善血流动力学状况和临床症状。在以前研究显示,奈西立肽存在安全性问题,即增高30 d病死率和肾功能损害的危险。最近的意见是,只要我们应用推荐剂量[0.01μg/(kg.min)±负荷剂量],奈西立肽对急性失代偿性心力衰竭患者似乎是安全有效的。现系统复习奈西立肽的一般知识,它在急性失代偿性心力衰竭患者使用的推荐剂量、临床疗效和安全性。 Nesiritide（rhBNP） is manufactured from escherichia coli using recombinant DNA technology and has the same chemical structure and biological effects as the BNP produced endogenously by the ventricular myocardium, rhBNP is a potent vasodilator which was approved by US FDA in 2001 for treatment of patients with acute decompensated heart failure（ADHF）. Foreign literatures had showed that rhB- NP may rapidly improve hemodynamic status and clinical symptom of ADHF. In prior study,the safety of rhBNP has been questioned,and rh- BNP was found to increase 30-day mortality and risk for renal impairments. Recent opinion in this regard is that so long as we use recommend dose （0.01μg·kg^-1·min^-1± bolus） rhBNP appear to be safe and effective in patients with ADHF.
作者 胡康新 陈伊 胡佩
机构地区 南昌市医学科学研究所
出处 《心血管病学进展》 CAS 2013年第2期199-203,共5页 Advances in Cardiovascular Diseases
关键词 奈西立肽 急性失代偿性心力衰竭 推荐剂量 肾功能 30 d病死率 nesiritide acute decompensated heart failure recommend dose renal function 30-day mortality
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献27

  • 1US Food and Drug Administration. The Food and Drug Administration ( FDA ) has approved natrecor(nesiritide) injection for the treatment of acute congestive heart failure ( CHF ) [ R ]. New York : FDA Talk Paper, 2001 : 1-36.
  • 2胡康新.脑利钠肽在心力衰竭中的应用述评[J].现代诊断与治疗,2012,23(4):193-198. 被引量：1
  • 3Kogler H, Schott P, Toischer K, et al. Revalence of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca^2 + ATPase ex- pression [ J ]. Circulation ,2006,113:2724-2732.
  • 4Shah SJ, Michaels AD. Acute effects of intravenous nesiritide on cardiac contrac- tility in heart failure[ J]. J Cardiac Fail,2010,16:720-727.
  • 5Mills RM ,le Jemtel TH, Horton DE, et al. Sustained hemodynamic effects of an infusion of nesirltide (human B-type natriuretic peptide) in heart failure:a ran- domized, double-blind, placebo-controlled clinical trial. Natricor Study Group [ J ]. J Am Coil Cardiol, 1999,34 ( 1 ) : 155 -162.
  • 6Colucci WS, Elkayam U, Hortom DE, et al. Intravenous nesifitide, a natriuretic peptide,in the treatment of deeompensated congestive heart failure. Nesiritide study group[ J]. N Engl J Med,2000,343 (4) :246-253.
  • 7Burger A J, Horton DE,le Jemtel T,et al. Effect of nesifitide (B-type natriuretic peptide) and dobutamine on ventrieular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study [J]. Am Heart J,2002,144(6) :1102-1108.
  • 8Publication Committee for the VMAC investigator( Vasodilation in the Manage- ment of Acute CHF) the VMAC investigator. Intravenous nesiritide vs nitroglyc- erin for treatment of decompensated congestive heart failure : a randomized con- trolled trial[ J]. JAMA, 2002,287 (12) : 1531-1540.
  • 9Peacock WF,Emerman CL,Silver MA. Nesiritide added to standard care favora- bly reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure [ J ]. Am J Emerg Med, 2005,23 ( 3 ) : 327-331.
  • 10Yancy CW, Salzberg M, Berkowitz RI. Management of patients with congestive heart failure after hospitalization : results from the follow up serial infusions of nesiritide(FUSION) trial[ J]. J Card Fail,2003, ( suppl 5) :5232-5238.

二级参考文献47

  • 1Maisel AS,Krishmaswamy P,Nowak RH,et al.Rapid measurement of B-type natriuretic peptide in the emergemcy diagnosis of heart failure[J].NEngl J Med,2002,347(3):161-167.
  • 2Sudoh T,Kangawa K,Minamino N,et al.A new natriuretic peptide inporcine brain[J].Nature,1988,332:78-81.
  • 3Cowie MR,Jourdain P,Maisel A,et al.Clinical applications of B-type na-triuretic peptide(BNP)testing[J].Eur Hear J,2003,24(19):1710-1718.
  • 4Ogeser M,Jacob K.B-type natriuretic peptide(BNP)validation of an im-mediate response assay[J].Clin Lab,2001,47:23-29.
  • 5Lanchbury JG,Cambell E,Frampton CM.et al.Brain natrivretic peptideand N-terminal brain natriuretic peptide in the diagnosis of heart failurein patients with acute shortness of breath[J].J Am Coll Cardiol.2003,42(4)728-735.
  • 6McNairy M,Garletto N,Slopton P,et al.Stability of B-type natriureticpeptide level during exercise in patients with congestive heart failure:im-plication to outpatient monitoring with B-type natriuretic peptide[J].AmHeart J,2002,143:406-411.
  • 7Almeida SS,Agevedo A,Castro A,et al.B-type natriuretic peptide is re-lated to left vemtricular mass in hypertensive patients but not in athletes[J].Cardiology,2000,98:113-115.
  • 8Michaels AD,Andrew K,Madden JA,et al.Effects of intravenous nesirit-ide on human coronary vasomotor regulation and myocardial oxggen up-take[J].Circulation,2003,107(21):2697-2701.
  • 9Nizuma S,Iwanaga Y,Yahata T,et al.Impact of left ventricular and dias-tolic wall stress on plasma B-type natriuretic peptide in heart failure withchronic kidney disease and end-stage renal disease[J.] Clin Chem,2009,55:1347-1353.
  • 10Luchner A,Muders F,Dietl O,et al.Differential expression of cardiacANP and BNP in a rabbit model progressive left ventricular dysfunction[J].Cardiovasc Res,2001,51:601-607.
心血管病学进展
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部